Ultimovacs ASA (OSL:ULTI)
kr 1.82 0.032 (1.79%) Market Cap: 62.62 Mil Enterprise Value: -104.77 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 30/100

Q2 2024 Ultimovacs ASA Earnings Call Transcript

Aug 21, 2024 / 12:00PM GMT
Release Date Price: kr3.03 (-11.40%)
Carlos Sousa
Ultimovacs ASA - Chief Executive Officer

Good afternoon, everybody, and welcome to Ultimovacs second-quarter 2024 business update and financial results. As usual, I have with me our Chief Medical Officer, Jens Bjørheim; and our Chief Financial Officer, Hans Vassgård Eid. We will go through the main news from this quarter. (Event Instructions)

If we can move to the next slide, I have to show you the disclaimer. And if we move to the next slide, I will give a brief introduction. Jens will cover the clinical update on UV1. I will have a slide on our novel drug conjugation platform. Hans will cover the financial update, and then I will cover the news flow and end the meeting before Q&A.

Okay. So let's proceed and move to the next slide. Again, this quarter was mainly impacted by the results of INITIUM, FOCUS. Of course, despite these disappointing results and we are sorry for patients. We are still committed as a company and as a team to bring in UV1 across the next important data point, that is the DOVACC readout.

These top line results, as you know, the FOCUS

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot